|
|
 |
|
Diversity and Inclusion in Action at Schering-Plough |
|
| |
|
Schering-Plough's
commitment to diversity and inclusion is a visible, tangible one,
embodied in the work of the Office of Global Diversity &
Inclusion, the
Global Diversity and Inclusion Leadership Council and Colleague Networks.
The Company's efforts have been recognized with numerous awards
and top rankings from organizations and publications focused
on diversity. Recent honors include the following:
• Recognized by readers of Diversity/Careers in Engineering
and Information Technology as a Best Diversity Company in 2007
• Designated by the Human Rights Campaign in 2007 as one of
the Best Places to Work for GLBT Equality, earning a perfect
score on the Corporate Equality Index that rates treatment of
gay, lesbian, bisexual and transgender employees
• Named to the list of 100 Best Companies for Working Mothers
by Working Mother magazine in 2007 - an honor earned every
year since 2000.
Work/Life Effectiveness
A critical part of our diversity and inclusion strategy is a commitment
to making it easier for colleagues to find the right balance between
the competing demands of career and personal life. Many Schering-Plough
programs are customized to the needs of the varied lifestyles, and
personal, family and community responsibilities of our colleagues.
The work/life benefits differ among our global locations based on
local market practice, but generally include programs such as
child/elder care assistance, domestic partner benefits, flexible
work arrangements and educational opportunities.
|
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
